Hepatitis B virus and renal transplantation

Area of Science:

• Nephrology
• Hepatology
• Transplantation Medicine

Background:

• Hepatitis B virus (HBV) infection is a significant threat to liver health and survival in renal transplant (RT) patients.
• Despite past prevention efforts, HBV transmission persists in hemodialysis units, and organ transplantation from high-prevalence areas introduces ongoing risks.
• HBV infection post-RT can lead to severe liver complications like decompensated cirrhosis and hepatocellular carcinoma.

Purpose of the Study:

• To review the current landscape of Hepatitis B virus infection in renal transplant candidates and recipients.
• To highlight the persistent challenges and evolving risks associated with HBV in the context of chronic kidney disease and transplantation.
• To discuss the impact of recent therapeutic advancements on managing HBV in this vulnerable population.

Main Methods:

• Literature review and synthesis of existing data on HBV prevalence, transmission, and outcomes in renal transplant populations.
• Analysis of the implications of chronic kidney disease and organ donor characteristics on HBV risk.
• Evaluation of the role of current and emerging antiviral therapies in mitigating HBV-related complications post-transplantation.

Main Results:

• Hepatitis B virus remains a critical concern, impacting survival and leading to serious liver disease, including cancer, in renal transplant recipients.
• Outbreaks of HBV infection continue to occur in patients with chronic kidney disease undergoing hemodialysis, and organ transplantation from endemic regions contributes to the risk pool.
• The availability of effective oral antiviral therapies has significantly improved the outlook for managing HBV infection and reducing its progression after renal transplantation.

Conclusions:

• Vigilance and proactive management of Hepatitis B virus are essential in the renal transplant population to prevent severe liver disease and improve patient survival.
• Ongoing transmission risks necessitate continued public health efforts and improved screening protocols.
• Advances in oral antiviral therapy represent a major breakthrough, offering better control and reduced progression of HBV infection post-renal transplantation.